Ptc Therapeutics (PTCT) Inventory Average (2017 - 2026)

Ptc Therapeutics' Inventory Average history runs 10 years deep, the most recent figure standing at $77.6 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 245.93% year-over-year to $77.6 million in Q1 2026; TTM through Mar 2026 was $77.6 million, a 245.93% increase from a year earlier, with the FY2025 full-year figure at $51.4 million, up 91.26% from the prior year.
• Inventory Average rose to $77.6 million in Q1 2026 per PTCT's latest filing, from $66.2 million in the prior quarter.
• Across five years, Inventory Average topped out at $77.6 million in Q1 2026 and bottomed at $14.9 million in Q3 2022.
• The 5-year median for Inventory Average is $29.4 million (2024), against an average of $32.1 million.
• Across the five-year window, Inventory Average slipped 26.0% in 2025 and surged 245.93% in 2026, its largest moves.
• Year by year, Inventory Average stood at $18.3 million in 2022, then surged by 81.13% to $33.2 million in 2023, then retreated by 11.25% to $29.4 million in 2024, then surged by 124.81% to $66.2 million in 2025, then increased by 17.29% to $77.6 million in 2026.
• Per Business Quant, the three latest PTCT Inventory Average figures stand at $77.6 million (Q1 2026), $66.2 million (Q4 2025), and $43.4 million (Q3 2025).